According to a newly published market research report by 24LifeSciences, the global Lumateperone market was valued at USD 315 million in 2024 and is projected to reach USD 1.23 billion by 2031, growing at a compound annual growth rate (CAGR) of 24.3% during the forecast period 20252031. Lumateperone, commercially known as Caplyta, is a novel second-generation antipsychotic medication approved...